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atients With Advanced Heart Failure
ohn N. Nanas, MD, PHD, FESC,* Charis Matsouka, MD,† Drosos Karageorgopoulos, MD,*
nastasia Leonti, MD,‡ Elias Tsolakis, MD,* Stavros G. Drakos, MD,* Eleftheria P. Tsagalou, MD,*
eorge D. Maroulidis, MD,* George P. Alexopoulos, MD,* John E. Kanakakis, MD,*
aria I. Anastasiou-Nana, MD, FESC*
thens, Greece
OBJECTIVES We prospectively investigated the causes of anemia in patients with advanced congestive heart
failure (CHF).
BACKGROUND Anemia is common in patients with advanced CHF, and its etiology is generally considered
to be multifactorial. However, despite its importance, precise information is lacking regarding
the prevalence of putative etiologic factors.
METHODS Patients who were hospitalized for decompensated advanced CHF and who were stabilized
after their initial treatment underwent evaluation of “clinically significant” anemia, defined as
a hemoglobin content 12 g/dl for men and 11.5 g/dl for women. Patients with a serum
creatinine concentration 3 mg/dl or patients with concurrent diseases that are known to
cause anemia were not included. The initial evaluation included measurements of vitamin
B12, folic acid, thyroid-stimulating hormone, erythropoietin, lactate dehydrogenase, Coombs
test, multiple fecal occult tests, and bone marrow aspiration. Patients without diagnosis by
these methods underwent red cell mass measurement with 51Cr assay.
RESULTS The mean age of the 37 patients was 57.9  10.9 years and mean left ventricular ejection
fraction 22.5 5.9%. Iron deficiency anemia was confirmed by bone marrow aspiration in 27
patients (73%), 2 patients (5.4%) had dilutional anemia, and 1 patient (2.7%) had
drug-induced anemia. No specific cause was identified in 7 patients (18.9%) who were
considered to have “anemia of chronic disease.” Serum ferritin for the iron-deficient patients
was not a reliable marker of iron deficiency in this population.
CONCLUSIONS In this group of patients, iron deficiency was the most common cause of anemia. The iron
status of patients with end-stage chronic CHF should be thoroughly evaluated and corrected
before considering other therapeutic interventions. (J Am Coll Cardiol 2006;48:2485–9)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.034© 2006 by the American College of Cardiology Foundation
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the 1-year death rate of patients suffering from congestive
eart failure (CHF) refractory to standard medical treat-
ent exceeds 50% (1). Furthermore, deaths attributed to
HF have increased 145% in the last 2 decades (2). This
ncreased death rate, despite advances in medical treatment,
oints to the importance of identifying factors related to
oor outcomes and developing new treatment and preven-
ion modalities.
See page 2490
In 2000, Silverberg et al. (3) published the first report of
decrease in blood hemoglobin content with increasing
everity of CHF. Since then, several studies have docu-
ented both a greater mortality associated with anemia
4–12) and a high prevalence of anemia (3,5,13,14) in
atients with advanced CHF. In small, randomized studies,
he elimination of anemia significantly improved cardiac
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006, accepted August 7, 2006.unction, functional capacity, and quality of life of patients
ith advanced CHF (15,16).
Although the optimal treatment of anemia must target its
nderlying mechanisms, only a few studies have thoroughly
nvestigated the causes of anemia in patients suffering from
HF, and almost none at all the causes in patients with
dvanced heart failure, intractable to standard medical
reatment. The purpose of this study was to prospectively
xamine the etiology of anemia in patients presenting with
nd-stage CHF.
ETHODS
atient population and methods. This study included 37
onsecutive patients suffering from end-stage CHF and
nemia who had been treated with an optimal medical
egimen and were hospitalized for management of acute
ardiac decompensation, which did not respond to oral
edical treatment and which required continuous intrave-
ous infusions of dobutamine 10 g/kg/min for not more
han 72 h. This group of patients was selected by prospec-
ively screening all patients who had been hospitalized for
cute decompensated advanced heart failure and had re-
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Anemia in Heart Failure December 19, 2006:2485–9ponded to intravenous dobutamine infusion. To guide their
reatment, we submitted all patients to baseline right heart
atheterization. The blood hemoglobin content, measured
fter the discontinuation of dobutamine, was 12 g/dl in
en and 11.5 g/dl in women. Patients with chronic renal
nsufficiency and a serum creatinine concentration3 mg/dl
r a history of comorbid disorders known to cause anemia,
uch as hypothyroidism, hereditary anemia, hematological
isease or known diseases that cause gastrointestinal bleed-
ng, were excluded from the study.
After stabilization of their clinical status, all patients
nderwent a detailed evaluation including electrocardio-
ram, chest radiograph, echocardiogram, and baseline right
eart catheterization. The creatinine clearance was esti-
ated on the base of the Cockroff-Gault formula. Tests in
earch of an etiology of anemia included measurements of
erum iron, ferritin, erythropoietin, folic acid, vitamin B12,
hyroid-stimulating hormone, lactate dehydrogenase, biliru-
in, Coombs test, albumin, globulin, creatinine, C-reactive
rotein, fecal occult blood test repeated 3 times, and bone
arrow aspiration. Iron deficiency on bone marrow biopsy
as defined as absence of iron stores. When the etiology of
nemia was not clarified by these investigations, the patients
nderwent red cell mass measurement by 51Cr assay (17). At
he conclusion of the evaluation, patients were classified into
hose having 1) iron deficiency anemia, 2) anemia of chronic
isease, 3) drug-induced anemia, and 4) hemodilutional
nemia. The ethical review board of our institution ap-
roved this study, and all patients had granted their written
nformed consent to participate.
tatistical analysis. Anemia was prespecified as a blood
emoglobin content 12 g/dl in men, and 11.5 g/dl in
omen, after clinical stabilization. Data are presented as
ean values  SD. Differences between patients with iron
eficiency anemia versus patients with anemia not due to
ron deficiency were examined by using the Student t test for
npaired observations, for continuous variables. Survival
omparisons between patient subgroups were estimated by
he Kaplan-Meier method and the log rank test. The
oncentrations of biochemical compounds were compared
ith standard normal values.
ESULTS
linical characteristics and hemodynamic measurements.
he mean age of the 35 men and 2 women included in this
tudy was 57.9  10.9 years. All patients were in New York
eart Association (NYHA) functional class IV upon ad-
ission to the hospital. After stabilization by intravenous
Abbreviations and Acronyms
CHF  congestive heart failure
NYHA  New York Heart Associationrug treatment, the mean NYHA functional class was 3.7 v.5, mean pulmonary capillary wedge pressure 25.8  7.5
m Hg, and mean left ventricular ejection fraction 22.5 
.9% (Table 1).
ematological and biochemical observations. The re-
ults of the hematological and biochemical investigations in
he 37 patients are shown in Table 2. The mean hemoglobin
as 10.4  0.8 g/dl on admission to the hospital and 10.1 
.9 g/dl (range 8.8 to 12.0) after initial stabilization, the
erritin concentration was low (17 ng/ml) in 2 patients
nd within normal limits (17 to 390 ng/ml) in the remainder
f the population, and the mean erythropoietin concentra-
ion was 68.6  54.7 U/ml, more than double the upper
ormal limit (9 to 30 U/ml) of our laboratory. The serum
reatinine averaged 1.7 mg/dl and 56.7% were greater than
he normal values of 1.4 mg/dl. Bone marrow aspirations
onfirmed the presence of iron deficiency in 27 of the 37
atients. In addition, 3 separate detection tests for occult fecal
lood were negative in 89% of iron-deficient patients and in all
on–iron-deficient patients.
The mean age, NYHA functional class, and indexes of
ardiac and hemodynamic function in the 27 iron-deficient
able 1. Baseline Clinical Characteristics and Hemodynamic
easurements After Stabilization of 37 Patients With
dvanced Congestive Heart Failure and Anemia
ge, yrs 57.9  10.9
en/women, n 35/2
uration of heart failure, months (median) 60
emoglobin concentration, g/dl 10.1  0.9
ematocrit, % 32.1  2.8
ew York Heart Association functional class 3.7  0.5
eart rate, beats/min 76.1  9.8
ystolic blood pressure, mm Hg 96.6  9.2
iastolic blood pressure, mm Hg 59.8  10.8
ean right atrial pressure, mm Hg 13.6  6.9
ight ventricular systolic pressure, mm Hg 61.6  15.5
ean pulmonary artery pressure, mm Hg 40.4  10.3
ulmonary capillary wedge pressure, mm Hg 25.8  7.5
ardiac index, l/m2/min 1.9  0.5
ulmonary vascular resistance, Wood units 4.3  2.1
eft ventricular ejection fraction, % 22.5  5.9
eft ventricular end-diastolic diameter, mm 70.9  6.7
erum creatinine, mg/dl 1.7  0.6
reatinine clearance, ml/min (Cockcroft) 51.7  23.0
erum sodium, mEq/l 136  4
ody weight, kg 74.6  11.6
ody mass index, kg/m2 25  4
oncomitant drug therapy, % of patients
Furosemide 100
Digoxin 45.9
Angiotensin-converting enzyme inhibitors 56.8
Spironolactone 73
Metoprolol 10.8
Carvedilol 5.4
Amiodarone 89.2
Aspirin/clopidogrel 48.6
Warfarin 32.4
aily furosemide dose, mg 450  291
nless specified otherwise, values are mean  SD.ersus the 10 non–iron-deficient patients were similar. With
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December 19, 2006:2485–9 Anemia in Heart Failureespect to hematological measurements, mean corpuscular
olume, mean corpuscular hemoglobin, and ferritin concen-
ration were significantly lower among the iron-deficient
atients than among patients with anemia not due to iron
eficiency (Table 3).
The 3-month mortality rate in the overall patient popu-
ation was 46%. All deaths were due to worsening of CHF.
he survival rates of iron-deficient and non–iron-deficient
atients estimated by the Kaplan-Meier method were sim-
lar (44.4% vs. 50.0%, respectively, p  0.83).
tiology of anemia. In the studied group of 37 anemic
atients, iron deficiency was confirmed in 27 (73%), as
reviously stated. The blood volume analysis with 51Cr-
abeled erythrocytes revealed that 2 patients (5.4%) had normal
ed blood cells volumes (95% predicted, i.e., 31.8  3.5
l/kg body weight). Furthermore, 1 patient (2.7%) had
nalapril-induced anemia, which resolved upon treatment
iscontinuation, and returned upon treatment rechallenge.
o specific cause was identified in 7 patients (18.9%), who
ere classified as suffering from anemia of chronic disease
Fig. 1).
able 2. Hematological and Biochemical Measurements After
linical Stabilization in 37 Patients With End-Stage Heart
ailure and Anemia
ematocrit, % 32.1  2.8
emoglobin, g/dl 10.1  0.9
ean corpuscular volume, fl 82.6  8.5
ean corpuscular hemoglobin, pg 26.3  3.4
erum iron, /dl 52.2  23.6
erritin, ng/ml 113.2  94.4
rythropoietin, U/ml 68.6  54.7
itamin B12, pg/ml 867  443
olic acid, ng/ml 10.2  4.7
hyroid-stimulating hormone, IU/ml 4.4  5.8
-reactive protein, mg/dl 3.4  3.8
alues are expressed as mean  SD.
Table 3. Baseline Hematological and Biochem
Non–Iron-Deficient Patients
Iron
(
Hemoglobin, g/dl 10
Hematocrit, % 32
Mean corpuscular volume, fl 80
Mean corpuscular hemoglobin, pg 25
Iron, /dl 51
Ferritin, ng/ml 75
Erythropoietin, U/ml 74
Fibrinogen, g/l 349
C-reactive protein, mg/dl 2
Erythrocyte sedimentation rate, mm/h 39
Serum sodium, mEq/l 135
Daily dose of furosemide, mg 428
Brain natriuretic peptide, pg/ml 1,283
Serum creatinine, mg/dl 1
Creatinine clearance, ml/min 53
Thyroid-stimulating hormone, IU/ml 3Values are expressed as mean  SD.ISCUSSION
n this group of patients with end-stage CHF and anemia,
high prevalence of iron deficiency was observed, accom-
anied by an inappropriately low erythropoietin and normal
erritin concentrations. Until recently, the role of anemia in
atients with CHF has been underestimated. However,
ecent studies have shown that an increasing severity of
nemia is associated with increasing mortality in patients
ith CHF (4–11,18).
The patients included in the present study had end-stage
HF and, despite all having been treated with maximally
olerated doses of oral medications, including high doses of
urosemide, continued to have disabling dyspnea at rest.
herefore, they were all initially treated with additional
ontinuous intravenous infusion of inotropes and, subse-
uently, intermittent infusions of inotropes and oral amio-
arone (19). After their initial stabilization, they remained
n NYHA functional classes III to IV, with markedly
levated pulmonary capillary wedge pressures. The 3-month
easurements in Iron-Deficient Versus
cient
7)
Non–Iron Deficient
(n  10) p Value
.9 10.0  0.9 0.61
.8 31.1  2.9 0.28
.8 87.7  5.2 0.024
.4 28.5  2.3 0.014
3.3 54.6  25.7 0.73
9.1 211.9  99.9 0.00001
8.2 52.3  42.3 0.27
8.3 485.1  124.1 0.0002
.5 4.7  4.6 0.22
1.9 65.9  26.7 0.005
.2 138.6  4.9 0.0162
88.1 510.5  306.3 0.46
,260.0 1,670.0  1,950.7 0.53
.6 1.7  0.6 0.75
5.1 47.9  16.4 0.54
.9 5.6  8.0 0.46
igure 1. Distribution of various etiologies of anemia among 37 patients
ith advanced congestive heart failure.ical M
Defi
n  2
.2  0
.4  2
.7  8
.5  3
.3  2
.3  5
.8  5
.8  6
.9  3
.6  2
.1  3
.7  2
.7  1
.7  0
.1  2
.9  4
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Anemia in Heart Failure December 19, 2006:2485–9ortality rate in this population was inordinately high and
omparable with that observed among patients requiring
reatment with combined intravenous inotropes (20). This
ndicates that patients with cardiac decompensation and
nemia are a population suffering from extremely severe
HF.
The high prevalence of iron deficiency anemia in these
esperately ill patients, which probably plays a causative role
n the progression of CHF, seems to be multifactorial, and
t least partially the result of a defective release of iron from
ells (21). Poor nutrition is common in advanced CHF (22),
nd both an insufficient dietary iron intake from acquired
astrointestinal malabsorption and chronic blood loss from
he prophylactic use of aspirin and uremic gastritis may
recipitate iron deficiency anemia (23). Iron deficiency has
een observed in 21% of anemic patients suffering from
HF (7).
In contrast to other studies in which the type of anemia
as diagnosed on the basis of hematological and biochem-
cal testing, this study ascertained beyond doubt the diag-
osis of iron deficiency anemia by verifying the absence of
ron in the bone marrow. Iron deficiency anemia, in our
atients, was not associated with the expected decrease in
erritin concentrations. This relative increase in ferritin
oncentrations might be the result of the inflammation that
ccompanies the CHF syndrome (24). Similarly the rela-
ively low erythropoietin could be attributable to either
ytokine inhibition of erythropoietin production on the
idney and/or to the associated renal failure. The increased
-reactive protein concentrations measured in our patients
ere a distinct indication of the presence of inflammation.
ole of hemodilution. A low hemoglobin concentration
ay be the consequence of an increased plasma volume and
ormal red blood cell volume (25). Androne et al. (26) have
eported a 46% prevalence of hemodilution in anemic
atients with advanced CHF. In our study, 5.4% of the
atients had findings consistent with hemodilution and not
rue anemia. However, the presence of hypervolemia does
ot preclude the coexistence of true anemia. The discrep-
ncy between the 2 studies has several potential explana-
ions. First, in our study, measurements of the red blood cell
olume were limited to 9 patients in whom the evaluation
id not reveal the presence of iron deficiency or of another
pecific cause of anemia. Among these 9 patients, 2 had
seudo-anemia due to hemodilution, and 1 patient had
nemia of chronic disease and hypervolemia. Therefore,
mong the patients whose red blood cell volume was
easured, 33% were found to have hemodilution. Second,
ifferences in techniques of blood volume measurements
51Cr assay in our study versus radiolabeled albumin in the
tudy by Androne et al. [26]) and the small number of
atients included in both studies might have contributed to
his discrepancy. Third, iron-deficient patients also might
e hemodiluted. Considering all these factors, the preva-
ence of hemodilution in our study versus that of Androne
t al. (26) seems similar.ole of chronic disease. Anemia in patients with advanced
HF may be caused by bone marrow suppression (27).
nterleukin-1 and tumor necrosis factor- directly inhibit
he in vitro production of erythropoietin in patients with
nflammatory disorders who commonly exhibit a blunted
esponse of erythropoietin to anemia (27,28). Elevated
lasma concentrations of tumor necrosis factor- interfere
ith the peripheral effects of erythropoietin (29,30). In our
atients, the erythropoietin concentrations were elevated,
lthough not to a level commensurate with their degree of
nemia. This blunted elevation of erythropoietin may be a
onsequence of treatment with angiotensin-converting en-
yme inhibitors (31), or of the chronic renal insufficiency
hat frequently complicates CHF, or both. In our study, 21
f 37 patients (57%) had a serum creatinine 1.5 mg/dl. In
he study by Cromie et al. (32), 46% of anemic patients had
enal insufficiency, whereas Ezekowitz et al. (7) reported
hat anemic patients were more likely to suffer from chronic
enal insufficiency. Anemia is common in CHF despite
levated concentrations of erythropoietin, suggesting the
xistence of target organ resistance to its effects.
tudy limitations. The observations of our study were
ade in, and should be limited to, a distinct population of
atients with end-stage and recently decompensated CHF.
nother limitation of the study was the small proportion
f patients who underwent measurements of red cell vol-
me. However, the high prevalence of hemodilution in
nemic patients suffering from CHF warrants further
nvestigations.
onclusions. Our results suggest that the majority of
nemic patients with advanced CHF are iron deficient,
uggesting that a trial of iron-replacement therapy in
atients presenting with advanced CHF and anemia is
mperative.
eprint requests and correspondence: Dr. John N. Nanas,
4 Makedonias, 10433 Athens, Greece. E-mail: jnanas@ath.
orthnet.gr.
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